Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease, affecting up to 30% of the world population. Its effects range from simple fat accumulation (steatosis) to inflammatorymediated fibrosis or cirrhosis – the most severe form of the disease called metabolic dysfunction-associated steatohepatitis (MASH). It is estimated that 20-25% of MASLD patients will advance to MASH during their lifetime, placing them at significantly increased risk for liver failure or liver cancer.
As a leading laboratory services organization for trials across the globe, we integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize your MASLD or MASH study design, assuring high-quality data delivery and regulatory approval. Our network of laboratories offers services across the globe including anatomic pathology and biomarker delivery.
Download our fact sheet to learn about our capabilities supporting MASH and liver disease clinical trials.
Download Document